The company is developing technology that will detect cancer from just a single blood sample, enabling early treatment of the disease. The funding round included existing investors F-Prime Capital, OrbiMed and Deerfield Management, as well as newcomer Labcorp. (The Logic)
Talking point: Adela’s headquarters is in California, but its technology was first developed by chief scientific officer Dr. Daniel De Carvalho at The Princess Margaret Cancer Centre in Toronto, and it maintains an office in the city. It plans to use the money to further develop its tech platform and commercialize its first product, which is for monitoring for small numbers of cancer cells in the body (or “minimal residual disease”). Adela simultaneously announced that Lisa Alderson, who has been on the company’s board of directors since early last year, will become its interim CEO.